Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social

Thanks 🙏🏻 to @oncodaily.bsky.social to highlight the results of #IMPROVE trial Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic #CRC #GIonc #OncSky oncodaily.com/blog/panitum...

Exciting #GIonc INFINITY ♾ #Ph2 trial Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR 12m 🚫🔪#survival ~ 64%. #Ph3 data needed, but organ preservation possible! 🔗: sciencedirect.com/science/arti...

#GI25 @ascocancer.bsky.social For #colorectalcancer, there are many great abstracts-so this is just a few to🔦: Pre-op: 1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19 2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20

#GI25 @ascocancer.bsky.social The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16

#GI25 @ascocancer.bsky.social And 3 immunotherapy trials in #MCRC: 1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143 2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23 3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13

#GIonc summary top 3 trials in #crcsm 🥇: NICHE-2 - 99% #ORR, 100% 3-year DFS in dMMR colon cancer with ⬇️ #tox 🥈: KRYSTAL-1 - adagrasib in KRAS G12C cancers ➡️ FDA approval + cetux 🥉: TransMet - transplant + 💉 improves 5y #OS 🔗: nature.com/articles/s41...

Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social 👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️ 👉⬆️TOX G3 diarrhoea and rash

PD-1 blockade with Tislelizumab+chemoradiotherapy in unselected MMR locally advanced #rectalcancer doi.org/10.1038/s415... @natmedicine.bsky.social ✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively

Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer 🧪 #PancreaticCancer febs.onlinelibrary.wiley.com/doi/10.1002/...

#GI25 @ascocancer.bsky.social Finally, two additional abstracts to watch for in #cholangiocarcinoma: 1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18 2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9

#GI25 @ascocancer.bsky.social 3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma: 1⃣&2⃣look at MDM2amp BTC: ➡️Dr. Iyer, Abs 544; Post#A22 ➡️Teresa Macarulla, Abs 615, Post#D16 3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26

Many thanks to @mpishvaian.bsky.social to share his top abstract titles of the upcoming #GI25 @ascocancer.bsky.social #GIonc

A-REPEAT trial: #panitumumab based #rechallenge strategy in pretteated metastatic #crc pts. The study was closed prematurely but highlights the importance of #LiquidBiopsy before rechallenge:48% of pts were RAS mutant #GIonc #OncSky @christianrolfo.bsky.social www.sciencedirect.com/science/arti...

The OncoAlert🚨 Network along with our partners at ESSO, ESGO, MASCC & SIOG invite you to the #OncoAlertColloquium REGISTER for FREE HERE👉 buff.ly/3CChgre February 3-9, 2025 💯% Virtual & Interactive @erikahamilton9.bsky.social @drsgraff.bsky.social @drjnaidoo.bsky.social @hoperugo.bsky.social

Interesting review on advances in targeting 🎯#KRAS in #mCRC Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer by Dr.Dustin Deming on #JNCCN jnccn.org/view/journal... @oncoalert.bsky.social @oncodaily.bsky.social @medicalwatch.bsky.social

www.nature.com/articles/d41... The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !

Happy New Year to everyone! @oncodaily.bsky.social @oncoalert.bsky.social @medicalwatch.bsky.social @katesears.bsky.social

📢Very useful suggestions from @medicalwatch.bsky.social @katesears.bsky.social directly forwarded to your📁📬email. You can subscribe to get a monthly update on phase 3 interventional clinical trials recruiting near you on your field of interest. Congrats and thanks for this project!👏🏻💪🏻 #OncSky #GIonc

Another issue on the role of #LiquidBiopsy in #CRC 👉 In these patients with stage II-IV CRC who underwent curative-intent resection,the benefit of adding serial tumor-informed ctDNA assay to the standard surveillance was limited #ISLB #GIonc @oncoalert.bsky.social jamanetwork.com/journals/jam...

Dear Colleagues, Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨 @elisaagostinetto.bsky.social @drjnaidoo.bsky.social @lymphomadoc.bsky.social @realbowtiedoc.bsky.social @stephenvliu.bsky.social @drlestercoll.bsky.social @erikahamilton9.bsky.social

Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1... #OncSky #GIonc

Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1...

🙏🏻 Grateful to @medicalwatch.bsky.social and @katesears.bsky.social to promote the results of IMPROVE trial ascopubs.org/doi/pdf/10.1... in the weekly newsletter! To be always updated on most recent trials, you can subscribe at my.medical.watch/signup

A very interesting course here in Italy, very recommended to all oncology researchers @ascocancer.bsky.social

#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO ✅ Endpoint met 👉mPFS 11.2(C)vs17.5 months(I) 👉NO detrimental effect on OS 👉DCR 94.2%(C)vs91%(I) 👉Reduced toxicity ascopubs.org/doi/pdf/10.1...

@oncoalert.bsky.social @medicalwatch.bsky.social Historic milestone 🎯🥇 for first-line #mCRC treatment of #BRAF V600E mut patients based on #BREAKWATER study: FDA grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ mCRC patients #GIonc www.fda.gov/drugs/resour...

The FDA has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for first-line treatment in patients with metastatic colorectal cancer with a BRAF V600E mutation. The approval is based on the BREAKWATER study, for which MD Anderson’s Dr. Scott Kopetz is co-PI. 1/2

Great milestone 🎯🥇 for #mCRC treatment #GIonc #OncSky based on the last update clinicaltrials.gov/study/NCT046... FDA grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer www.fda.gov/drugs/resour...

Join Drs. Abou-Alfa, Goyal, Harding, & Prof. Vogel for a PeerView Live Symposium in collaboration with the CholangiocarcinomaFoundation.org during the #GI25 📅 Jan 23, 2025 🕕 Reg & Dinner: 6:00 PM PST 🕡 Symposium: 6:15 PM PST / 9:15 PM EST 📍 In-Person & Virtual #Medsky #Oncsky

ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC @fredhutch.bsky.social #crcsm #oncology www.onclive.com/view/ctdna-n...

Happy to find ASCO @ascocancer.bsky.social here on @bsky.app We were waiting for this day! A faster opportunity to get in touch with colleagues and another encouraging opportunity to share news! #OncSky #GIonc

New guideline just out from ASCO on systemic therapy for stage I-III anal squamous cell carcinoma #ASCOguidelines #MedSky #OncSky ascopubs.org/doi/full/10....

#OncSky #GIonc

SWOG S1815 shows no OS benefit for nab-paclitaxel in BTCs - Rachna T. Shroff @rachnatshroff.bsky.social oncodaily.com/science/rach... #AdvancedBiliaryCancer #BTCResearch #Cancer #Medicine #GemcitabineCisplatin #JCO #ASCO #NabPaclitaxel #Health #OncoDaily #Oncology #SWOG #S1815

my.medical.watch The weekly newsletter on CRC is now available for subscribers @medicalwatch.bsky.social @katesears.bsky.social

Happy to find ASCO @ascocancer.bsky.social here on @bsky.app We were waiting for this day! A faster opportunity to get in touch with colleagues and another encouraging opportunity to share news! #OncSky #GIonc

Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer #OncSky #GIonc @ascopost.bsky.social ascopost.com/news/decembe...

We've spent 2024 discussing RT trial results in gastroesophageal cancer. My radiation oncology mate Som helps me make sense of it all below... 2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change prac.co/l/22cfph7u

#GlobalOnc 🌎 study relevant to #GIonc #crcsm mortality ⬆️ in young adults (25–49) in 9 countries for men, 7 for women, driven by factors like obesity. More surveillance and prevention are needed‼️ 🔗: academic.oup.com/jnci/advance...

KRAS Variants Associated With Survival Outcomes & Genomic Alterations in Biliary Tract Cancers @JCOPO_ASCO doi.org/10.1200/PO.2... 👉 15% of BTC w/ KRAS mut 👉 KRAS G12D: IHC 38%; EHC 37% 👉 KRASG12 > worse outcome only in IHC 🧐We need KRASvariant specific strategies @myESMO @EASLedu

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer – Day 2 oncodaily.com/blog/global-... @manishshahmd.bsky.social #Medicine #Health #Oncology #OncoDaily #Cancer

Three new Pan-Asian-Adapted Guidelines from #ESMOAsia2024 #BTC #OncSky #GIonc dailyreporter.esmo.org/esmo-asia-co...

Interesting paper on #JAMA Oncology: long-term colorectal cancer incidence according to negative colonoscopy screening results and individuals’ risk profiles #OncSky #GIonc ja.ma/41o4Eyk

#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO ✅ Endpoint met 👉mPFS 11.2(C)vs17.5 months(I) 👉NO detrimental effect on OS 👉DCR 94.2%(C)vs91%(I) 👉Reduced toxicity ascopubs.org/doi/pdf/10.1...

Intermittent treatment with FOLFIRI plus panitumumab reduced toxicity and maintained effectiveness in colorectal cancer patients. by Avallone A, Giuliani F (...) Budillon A et 23 al. in J Clin Oncol #MedSky 📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00979

New in #JCO Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial #MCC #openaccess #oncsky ascopubs.org/doi/10.1200/...